Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
About this item
Full title
Author / Creator
de Wit, Ronald , de Bono, Johann , Sternberg, Cora N , Fizazi, Karim , Tombal, Bertrand , Wülfing, Christian , Kramer, Gero , Eymard, Jean-Christophe , Bamias, Aristotelis , Carles, Joan , Iacovelli, Roberto , Melichar, Bohuslav , Sverrisdóttir, Ásgerður , Theodore, Christine , Feyerabend, Susan , Helissey, Carole , Ozatilgan, Ayse , Geffriaud-Ricouard, Christine , Castellano, Daniel and CARD Investigators
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
A randomized trial involving patients with metastatic prostate cancer whose disease progressed after receipt of docetaxel and hormonal therapy showed that cabazitaxel was superior to an androgen-signaling–targeted agent in extending imaging-based progression-free survival, overall survival, and PSA response.
Alternative Titles
Full title
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Authors, Artists and Contributors
Author / Creator
de Bono, Johann
Sternberg, Cora N
Fizazi, Karim
Tombal, Bertrand
Wülfing, Christian
Kramer, Gero
Eymard, Jean-Christophe
Bamias, Aristotelis
Carles, Joan
Iacovelli, Roberto
Melichar, Bohuslav
Sverrisdóttir, Ásgerður
Theodore, Christine
Feyerabend, Susan
Helissey, Carole
Ozatilgan, Ayse
Geffriaud-Ricouard, Christine
Castellano, Daniel
CARD Investigators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2330624583
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2330624583
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1911206
